Tag: social capital
-
Social capital and evidence-based orientation shaping psychiatrists’ views on antipsychotic polypharmacy in schizophrenia
Understanding the debate: Antipsychotic polypharmacy in schizophrenia Antipsychotic polypharmacy (APP) — prescribing more than one antipsychotic medication simultaneously — remains a contentious practice in schizophrenia care. While some clinicians view APP as a necessary strategy to manage treatment-resistant symptoms or to augment partial responses, others warn of limited evidence, increased adverse events, and higher costs.…
-
Social Capital and Evidence-Based Orientation Shape Psychiatrists’ Views on Antipsychotic Polypharmacy in Schizophrenia
Introduction Antipsychotic polypharmacy (APP) remains a contentious practice in the treatment of schizophrenia. While some clinicians advocate for combining antipsychotics to address persistent symptoms or treatment resistance, others warn of increased side effects, drug interactions, and uncertain efficacy. Emerging research suggests that a psychiatrist’s social capital—the networks, alliances, and professional influence within their clinical and…
-
How Social Capital and Evidence-Based Orientation Shape Psychiatrists’ Views on Antipsychotic Polypharmacy in Schizophrenia
Overview: Why Attitudes Toward Antipsychotic Polypharmacy Matter Antipsychotic polypharmacy (APP) — the concomitant use of two or more antipsychotic drugs — remains a contentious issue in schizophrenia management. While some guidelines advise caution and careful monitoring, others acknowledge tailored approaches when monotherapy fails. Understanding what shapes psychiatrists’ attitudes toward APP is essential because clinician preferences…